IRCCS San Raffaele Scientific Institute in Milan, Italy, is looking for a Research Fellow position to join the Unit of Pathogenesis and Treatment of Immune and Bone Diseases, led by Anna Villa at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy.
Our Unit has a long-standing interest in the study of pathological mechanisms of immune and bone diseases and in the preclinical evaluation of innovative therapeutic approaches.
Main activities : The project, funded by Ministero della Salute, will be focused on the evaluation of innovative pre-transplant conditioning regimens based on antibody drug conjugates (ADC) to specifically target hematopoietic stem / progenitor cells with the final goal to preserve the bone marrow niche and improve the immunological reconstitution.
To this aim, we plan to characterize at phenotypical, functional, and molecular level both hematopoietic and non-hematopoietic compartments of bone marrow niche before and after conventional and innovative ADC conditionings in distinct mouse models of immune disorders.
Research activities will include animal handling, multiparametric flow cytometry, multiplex ELISA, and transcriptomic analysis.
Who we are looking for : We are looking for a highly motivated and creative researcher holding a degree in biomedical sciences (or equivalent).
Previous laboratory experience in mouse handling, cellular or molecular biology are welcome. Proficient English, proactive attitude mindset, excellent organizational skills and team spirit are required.
Work details : The successful candidate will be offered a 1-year renewable contract and the possibility to apply to a PhD program or a technician position.
The salary will be negotiated depending on experience. As part of the SR-TIGET, a world-leading Institute in the field of gene and cell therapy for the treatment of human genetic diseases, the candidates will benefit from a highly competitive, international and scientifically stimulating environment and offer excellent state-of-the-art facilities and infrastructures, and access to clinically relevant human samples.